Healome Therapeutics raises £2m to advance eye-drop matrix technology treating dry eye and ocular surface disease

Healome Therapeutics is a University of Birmingham spinout developing an eye-drop matrix technology that extends the residence time of therapeutics on the ocular surface. The platform is designed for use in dry eye disease, ocular surface inflammation, corneal injury and rare diseases causing severe ocular surface damage.